FDA will not fire staff pending Congress' move
This article was originally published in Clinica
As the US Congress left last week for its month-long recess without passing a major Food and Drug Administration reform bill, FDA Commissioner Andrew von Eschenbach vowed that the FDA would use reserve funds rather than layoff employees. House and Senate leaders could not agree on a reform bill, which contains numerous post-market safety changes as well as reauthorisation for medical device and drug user fee programmes, and so the law requires the agency FDA to begin sending "reduction in force" notices to employees paid by those programmes.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.